Updates and news related to prostate cancer:
Cambridge scientists have created a comprehensive tool for predicting an individual's risk of developing prostate cancer.
The FDA has granted 510(k) clearance to iQuest.
Clinical trials of new therapies
All patients with chemo-naïve metastatic castration-resistant prostate cancer experienced PSA decline, and half the cohort experienced a PSA decline greater than 50% after treatment with a novel PSMA-targeted radionuclide therapy.
The risk for febrile neutropenia from second-line docetaxel (Taxotere) is high in patients with metastatic castration-resistant prostate cancer, particularly for men older than age 75 years and those with multiple comorbidities.
The Prostate Cancer Foundation answers your questions!
How are patients getting information about cancer genetic testing?
Androgen deprivation therapy (ADT) sequenced during and after radiotherapy (RT) has clinical benefits for patients undergoing treatment for prostate cancer.
A leading proponent explains the arguments.
What affect do eggs, dairy, and supplements have on prostate cancer?